Germany Narcolepsy Therapeutics Market Report 2023 to 2030

Germany Narcolepsy Therapeutics Market Analysis

$ 3999

Germany narcolepsy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of narcoleptic disorders worldwide, rising stress levels, an ageing population, and growing public awareness of the variety of treatments for this condition are all predicted to have a positive impact on the market. Major global players in Narcolepsy Therapeutics Market are Avadel Pharmaceuticals Inc, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.

ID: IN10DERD051 CATEGORY: Rare Diseases GEOGRAPHY: Germany AUTHOR: Gaurav Bhongale

Buy Now

Germany Narcolepsy Therapeutics Market Analysis Summary

Germany Narcolepsy Therapeutics Market is valued at around $46.99 Mn in 2022 and is projected to reach $74.9 Mn by 2030, exhibiting a CAGR of 6% during the forecast period 2023-2030.

An excessive amount of GABA is released as a result of the neurological disorder narcolepsy, which keeps sufferers tired all day and makes it difficult to control one's sleep-wake cycle. People with narcolepsy endure daytime tiredness that makes it difficult for them to carry out everyday tasks as well as fast entry into REM sleep after falling asleep. They are also tremendously fatigued, have trouble focusing, and have vague recollections. The rising prevalence of narcoleptic disorders globally, rising stress levels, an increase in the number of elderly people, and improved awareness of the variety of treatment options available for this illness are a few factors that are projected to propel the market. For instance, a study titled "Prevalence, incidence, and health care use of patients with narcolepsy: a population-representative study" revealed that the early incidence of the illness in Europe ranges from 0.64 to 1.37 per 100,000 persons. The high frequency of the illness and rising use of narcolepsy medicines are expected to drive the market's growth in the next years. Major global players in this market are Avadel Pharmaceuticals Inc, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.

Market Dynamics

Market Growth Drivers

The rising prevalence of narcoleptic disorders globally, rising stress levels, an increase in the number of elderly people, and improved awareness of the variety of treatment options available for this illness are a few factors that are projected to propel the market. For instance, a study titled "Prevalence, incidence, and health care use of patients with narcolepsy: a population-representative study" revealed that the early incidence of the illness in Europe ranges from 0.64 to 1.37 per 100,000 persons. The high frequency of the illness and rising use of narcolepsy medicines are expected to drive the market's growth in the next years. ? Additionally, according to the article "Narcolepsy Presentation in Diverse Populations: an Update" published in November 2020, narcolepsy, namely narcolepsy type 1, affects 0.87 to 1.21 percent of the world's population. (NT1). The worldwide prevalence of narcolepsy is increasing the demand for narcolepsy therapies and driving the market's growth. The acceptance and marketing of novel medications by market participants may have a substantial impact on market growth in the following years.

Market Restraints

Market expansion will be hampered by the high cost of diagnosis and treatment as well as the unfavorable reimbursement environment. The market for treating narcolepsy would face difficulties since fewer manufacturers would be able to fund their specialized pharmaceutical research and development.

Key players

Jazz Pharmaceuticals UCB Almatica Pharma Somaxon Pharmaceuticals Catalyst Pharmaceuticals Neurocrine Biosciences Takeda Pharmaceutical Company Insmed Shionogi & Co., Ltd. Livanova

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Germany Narcolepsy Therapeutics Market Segmentation

By Type

Narcolepsy with Cataplexy
Narcolepsy without Cataplexy
Secondary Narcolepsy

By Product

Central Nervous System Stimulants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitors
Tricyclic Antidepressants
Other Products

By End-use

Hospital pharmacy
Retail pharmacy
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.